Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells 4,982 Shares

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 4,982 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $14.00, for a total value of $69,748.00. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,783,662. The trade was a 2.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Friday, June 26th, Aaron Tachibana sold 51,251 shares of Personalis stock. The shares were sold at an average price of $13.18, for a total value of $675,488.18.
• On Thursday, June 4th, Aaron Tachibana sold 40,000 shares of Personalis stock. The shares were sold at an average price of $12.01, for a total value of $480,400.00.
• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The stock was sold at an average price of $11.58, for a total value of $449,292.42.

Personalis Stock Performance

Shares of NASDAQ:PSNL traded up $0.73 during midday trading on Monday, hitting $13.75. 3,772,128 shares of the stock were exchanged, compared to its average volume of 2,086,146. The business’s 50-day moving average price is $8.42 and its 200 day moving average price is $8.28. Personalis, Inc. has a 12 month low of $3.84 and a 12 month high of $14.07. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -13.48 and a beta of 2.27.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The business had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. As a group, sell-side analysts expect that Personalis, Inc. will post -1.06 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Royal Bank of Canada increased its holdings in Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Personalis by 75.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after buying an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after buying an additional 101,706 shares during the period. Focus Partners Wealth bought a new stake in shares of Personalis in the 1st quarter valued at $47,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Personalis by 505.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock valued at $193,000 after acquiring an additional 24,621 shares in the last quarter. 61.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PSNL has been the topic of a number of analyst reports. Morgan Stanley reduced their price target on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Finally, BTIG Research decreased their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Personalis presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical?stage genomics company that develops and markets advanced next?generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T?cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno?oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in?depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.